KU Leuven, Department of Rehabilitation Sciences, Neurorehabilitation Research Group (eNRGy), 3000 Leuven, Belgium.
KU Leuven, Department of Rehabilitation Sciences, Research Group for Rehabilitation in Internal Disorders (GRID), 3000 Leuven, Belgium.
Sensors (Basel). 2023 Apr 21;23(8):4156. doi: 10.3390/s23084156.
Maintaining physical activity is an important clinical goal for people with Parkinson's disease (PwPD). We investigated the validity of two commercial activity trackers (ATs) to measure daily step counts. We compared a wrist- and a hip-worn commercial AT against the research-grade Dynaport Movemonitor (DAM) during 14 days of daily use. Criterion validity was assessed in 28 PwPD and 30 healthy controls (HCs) by a 2 × 3 ANOVA and intraclass correlation coefficients (ICC). The ability to measure daily step fluctuations compared to the DAM was studied by a 2 × 3 ANOVA and Kendall correlations. We also explored compliance and user-friendliness. Both the ATs and the DAM measured significantly fewer steps/day in PwPD compared to HCs ( < 0.01). Step counts derived from the ATs showed good to excellent agreement with the DAM in both groups (ICC > 0.83). Daily fluctuations were detected adequately by the ATs, showing moderate associations with DAM-rankings. While compliance was high overall, 22% of PwPD were disinclined to use the ATs after the study. Overall, we conclude that the ATs had sufficient agreement with the DAM for the purpose of promoting physical activity in mildly affected PwPD. However, further validation is needed before clinical use can be widely recommended.
保持身体活动是帕金森病患者(PwPD)的重要临床目标。我们研究了两种商业活动追踪器(ATs)测量日常步数的有效性。我们在 14 天的日常使用中,将腕戴和髋戴的商业 AT 与研究级 Dynaport Movemonitor(DAM)进行了比较。通过 2×3 ANOVA 和组内相关系数(ICC),在 28 名 PwPD 和 30 名健康对照组(HCs)中评估了标准效度。通过 2×3 ANOVA 和 Kendall 相关性,研究了与 DAM 相比测量日常步数波动的能力。我们还探讨了依从性和用户友好性。与 HCs 相比,两种 AT 和 DAM 在 PwPD 中每天测量的步数明显更少(<0.01)。在两组中,ATs 得出的步数与 DAM 具有良好到极好的一致性(ICC>0.83)。ATs 充分检测到日常波动,与 DAM 排名呈中度相关。虽然总体依从性较高,但 22%的 PwPD 在研究后不愿意使用 ATs。总体而言,我们得出结论,对于轻度 PwPD 促进身体活动的目的而言,ATs 与 DAM 具有足够的一致性。然而,在广泛推荐临床使用之前,还需要进一步验证。